Atopic Dermatitis

While Janus Kinase inhibitors are a fraction of what’s to come in dermatology, research from AAD VMX 2021 shows they represent the potential of unlocking new capabilities across the field.

A discussion on ease of access for dupilumab for the treatment of atopic dermatitis including the process for approval and coverage.

Examining the potential role for biologic, dupilumab, in the treatment of moderate to severe atopic dermatitis.

An assessment of real-world registry data suggest the biologic provides significant benefit outside of clinical trials.

A network meta-analysis shows favorability with dupilumab and abrocitinib in efficacy and safety outcomes among adults and adolescents.

Lawrence Eichenfield, MD, discusses future prescribing plans and safety assessment for the topical JAK 1/2 inhbitor.

New cross-sectional survey data suggest quality-of-life and psychological outcomes may differ in the most common chronic skin disease patient populations.

The investigative topical cream benefits adolescent and adult skin clearance and itch. A study author discusses keeping it available to patients if it reaches the market.

In a Q&A, Peter Lio, MD, discusses some evidence for using integrative therapies with patients.

The oral S1P receptor modulator has promise to break new ground for disease modification.

The investigative JAK inhibitor therapy provided significantly better skin clearance and resolved pain at 8 weeks with 2 different doses.

Rebecca Kazin, MD, offers some insight into her cosmetic dermatology practices, including a new hair product that she developed.

Phase 3 open-label extension data suggest young patients may even improve skin clearance scores after a year on the biologic therapy.

A review of the safety and efficacy of systemic agents such as methotrexate, azathioprine, and cyclosporine in patients with severe, persistent atopic dermatitis.

Experts in the management of atopic dermatitis review the safety and efficacy of topical calcineurin inhibitors and topical PDE4 inhibitors.

According to objective and subjective measures, children with more severe atopic dermatitis were more likely to report a learning disability.

Initial rates of common treatment-emergent adverse events from baricitinib 2 mg appear to remain stable or decrease with prolonged exposure.

Peter Lio, MD, and Elizabeth Swanson, MD, provide insight on using nonpharmacological therapies and state-of-the-art skin care treatments for patients with atopic dermatitis.

Patient factors considered when prescribing treatment options for the management of atopic dermatitis.

Some strains appear to reduce risk in pregnant women and infants.

A dermatologist discusses alternative and complementary options for the treatment of atopic dermatitis.

A dermatologist gives a broad overview of key considerations when determining a treatment course for pediatric patients.

Reviewing the importance of newer models of collaboration between specialty and primary care for atopic dermatitis and educating patients and caregivers for disease management.

Lawrence F. Eichenfield, MD; Jeffrey M. Bienstock, MD, FAAP; Peter A. Lio, MD; and Elizabeth A. Swanson, MD, discuss the importance of an integrative approach to care for the management of atopic dermatitis.

The oral Janus kinase 1 inhibitor abrocitinib produced similar outcomes to dupilumab in a placebo-controlled comparison for atopic dermatitis.